Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Motolimod. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 known ✓ | Q9NR97 | 20/20 | 1.00 |
| ▸ | TLR7 | Q9NYK1 | 14/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Motolimod SCHEMBL29353690 | 1.00 | TLR8 (1.00) | TLR8TLR7 | |
| SCHEMBL1803349 | 0.99 | TLR8 (0.98) | TLR8TLR7 | |
| SCHEMBL26080080 | 0.97 | TLR8 (0.95) | TLR8TLR7 | |
| SCHEMBL1801525 | 0.96 | TLR8 (0.93) | TLR8TLR7 | |
| SCHEMBL18772046 | 0.96 | TLR8 (0.93) | TLR8TLR7 | |
| SCHEMBL1238499 | 0.96 | TLR8 (0.92) | TLR8TLR7 | |
| SCHEMBL1801811 | 0.95 | TLR8 (0.90) | TLR8TLR7 | |
| SCHEMBL18771942 | 0.94 | TLR8 (0.89) | TLR8TLR7 | |
| SCHEMBL1238492 | 0.94 | TLR8 (0.89) | TLR8TLR7 | |
| SCHEMBL1238332 | 0.94 | TLR8 (0.88) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 161 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC | 2023-10-05 | — | — | US | claimed |
| WO-2023097237-A2 | CYTOSOLIC BACTERIAL PATHOGENS ATTENUATED FOR SPREAD FROM TUMORS AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-06-01 | — | — | WO | claimed |
| WO-2022047279-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | Accencio LLC (US) | 2022-03-03 | — | — | WO | claimed |
| EP-3195868-A2 | THERAPEUTIC USE OF A TLR AGONIST AND COMBINATION THERAPY | VentiRx Pharmaceuticals, Inc. (US) | 2017-07-26 | — | — | EP | claimed |
| EP-2621500-B1 | THERAPEUTIC USE OF A TLR AGONIST AND COMBINATION THERAPY | VENTIRX PHARMACEUTICALS INC (US) | 2016-11-23 | — | — | EP | claimed |
| US-9216192-B2 | Toll-like receptor agonist formulations and their use | VENTIRX PHARMACEUTICALS, INC. (US) | 2015-12-22 | — | — | US | claimed |
| EP-2313111-B1 | TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE | VENTIRX PHARMACEUTICALS INC (US) | 2013-09-04 | — | — | EP | claimed |
| EP-2621500-A2 | THERAPEUTIC USE OF A TLR AGONIST AND COMBINATION THERAPY | Ventirx Pharmaceuticals, Inc. (US) | 2013-08-07 | — | — | EP | claimed |
| US-8304407-B2 | 8-substituted benzoazepines as toll-like receptor modulators | ARRAY BIOPHARMA INC. (US) | 2012-11-06 | — | — | US | claimed |
| US-20120219615-A1 | Therapeutic Use of a TLR Agonist and Combination Therapy | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-08-30 | — | — | US | claimed |
| EP-1940797-B1 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | ARRAY BIOPHARMA INC (US) | 2012-08-01 | — | — | EP | claimed |
| US-20120165317-A1 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | ARRAY BIOPHARMA INC. (US) | 2012-06-28 | — | — | US | claimed |
| US-8153622-B2 | modulating a patient's immune system; treating autoimmunity, inflammation allergy, asthma, transplant rejection, graft versus host disease, infection, sepsis, cancer and immunodeficiency; (1E,4E)-ethyl 2-amino-8-(perfluoroethyl)-3H-benzo[b]azepine-4-carboxylate; antiinflammatory, anticarcinogenic agents | ARRAY BIOPHARMA INC. (US) | 2012-04-10 | — | — | US | claimed |
| WO-2012045090-A2 | THERAPEUTIC USE OF A TLR AGONIST AND COMBINATION THERAPY | VENTIRX PHARMACEUTICALS, INC. (US) | 2012-04-05 | — | — | WO | claimed |
| US-20080234251-A1 | 8-Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA INC. (US) | 2008-09-25 | — | — | US | claimed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-20080234251-A1 | 8-Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080234251-A1 | 8-Substituted Benzoazepines as Toll-Like Receptor Modulators | ARRAY BIOPHARMA INC. (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2007024612-A2 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | ARRAY BIOPHARMA INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | TLR8 2796/4885TLR7 3158/4885 |
| US-20120165317-A1 | 8-SUBSTITUTED BENZOAZEPINES AS TOLL-LIKE RECEPTOR MODULATORS | TLR8, TLR7, TLR9 | TLR8 1/4885TLR7 2/4885 |
| US-20120219615-A1 | Therapeutic Use of a TLR Agonist and Combination Therapy | TLR8, TLR3, TLR9 | TLR8 1/4885TLR7 4/4885 |
| US-20080234251-A1 | 8-Substituted Benzoazepines as Toll-Like Receptor Modulators | TLR8, TLR7, TLR9 | TLR8 1/4885TLR7 2/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | TLR8 2796/4885TLR7 3158/4885 |
| US-20230310469-A1 | METHODS OF TREATING SYMPTOMS OF CORONAVIRUS INFECTION WITH TOLL-LIKE-RECEPTOR AGONISTS | TLR3, TLR7, TLR8 | TLR8 3/4885TLR7 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.